<< Dean Evans & Associates rolls out new versions of facility scheduling and resource management tools | Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels >>

Read in | English | 简体中文

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Published on August 24, 2009 at 2:47 AM · No Comments

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

"The FDA's acceptance to file our pixantrone NDA represents a significant milestone for CTI and for patients with relapsed and refractory aggressive NHL. We look forward to working with the FDA and their final decision on our request for priority review," noted James Bianco, M.D., Chief Executive Officer of CTI.

Source: http://www.celltherapeutics.com

e711dc35-a372-4b8d-9eb3-afb0eb0a3b7f|0|.0

Posted in: Pharmaceutical News

Tags: Anthracycline, Breast Cancer, Cancer, Catheter, Cell, Chemotherapy, Congestive Heart Failure, Heart Failure, Hodgkin's Lymphoma, Leukemia, Lymphoma, New Drug Application, Non-Hodgkin's Lymphoma, Oncology, Prescription Drug

Related posts

Thrombocytosis linked to severity of ovarian cancerHighly elevated platelet levels fuel tumor growth and reduce the survival of ovarian cancer patients...
FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgeryNovartis announced today that following a priority review, the US Food and Drug Administration has ...
Neomatrix, UND partner to develop technology for early detection of breast cancerThe University of North Dakota and Neomatrix, LLC, have signed an exclusive agreement to develop tec...
CTI responds to EMA's Day 120 letter for pixantrone MAACell Therapeutics, Inc. today announced that it has submitted its response to the Day 120 List of Ou...
Allos Therapeutics reports results from FOLOTYN pivotal trial against peripheral T-cell lymphomaAllos Therapeutics, Inc. today reported results from a retrospective analysis of data from the Compa...
Phase 3 open-label study of RELISTOR presented at American Pain Society meetingSalix Pharmaceuticals, Ltd. today announced findings from two analyses of a Phase 3 open-label study...
First patient treated in Phase Ib expansion study of CUDC-101Curis, Inc., a drug development company seeking to develop next generation targeted small molecule d...
Study highlights importance of individualized, patient-centered therapiesIn an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the...
Report on the future market potential for monoclonal antibodiesReportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment
Reportlinker's report on spinal surgery marketReportlinker.com announces that a new market research report is available in its catalogue.
Delisheng shows anti-cancer effects on hepatocellular carcinomaTraditional Chinese medicine is world renowned. It has supernatural effects on some diseases, but th...
Sperm freezing for young male cancer patientsA recent study at Hamilton Health Sciences proves that sperm freezing and banking is an effective wa...
Lilly launches phase III trial of EnzastaurinOne of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli L...
Phase II clinical study of ularitideThe European Society of Cardiology (ESC) today highlighted results of a Phase II clinical study of u...
Chickenpox (Varicella) vaccine has saved the U.S. hundreds of millions of dollars since its introductionA new University of Michigan study has found that the Chickenpox (Varicella) vaccine has saved the U...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.